Alnylam Pharma (ALNY) Tops Q4 EPS by 6c, Misses on Revenue; Offers FY26 Revenue Guidance

Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of $1.25, $0.06 better than the analyst estimate of $1.19. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.15 billion.

GUIDANCE:

Alnylam Pharma sees FY2026 revenue of $4.9-5.3 billion, versus the consensus of $5.55 billion.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c
• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)